Logo do repositório
 
Publicação

Bisphosphonate-based molecules as potential new antiparasitic drugs

2020-06-03Recensão Acesso aberto
Ver registo simples
dc.contributor.authorBranco Santos, Joice Castelo
dc.contributor.authorde Melo, Jonathas Alves
dc.contributor.authorMaheshwari, Sweta
dc.contributor.authorde Medeiros, Wendy Marina Toscano Queiroz
dc.contributor.authorde Freitas Oliveira, Johny Wysllas
dc.contributor.authorMoreno, Cláudia Jassica
dc.contributor.authorMario Amzel, L.
dc.contributor.authorGabelli, Sandra B.
dc.contributor.authorSousa Silva, Marcelo
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionVector borne diseases and pathogens (VBD)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2021-05-01T22:52:53Z
dc.date.available2021-05-01T22:52:53Z
dc.date.issued2020-06-03
dc.description.abstractNeglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent20
dc.format.extent3051065
dc.identifier.doi10.3390/molecules25112602
dc.identifier.otherPURE: 26669253
dc.identifier.otherPURE UUID: 96ee863e-f1ba-46f5-95bc-961015a1529c
dc.identifier.otherScopus: 85086052217
dc.identifier.otherPubMed: 32503272
dc.identifier.otherPubMedCentral: PMC7321420
dc.identifier.urihttp://hdl.handle.net/10362/116627
dc.identifier.urlhttps://www.scopus.com/pages/publications/85086052217
dc.identifier.urlhttps://www.mdpi.com/1420-3049/25/11/2602
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBisphosphonate
dc.subjectChagas disease
dc.subjectFarnesyl pyrosphosphate synthase
dc.subjectLeishmaniasis
dc.subjectNeglected tropical diseases
dc.subjectChemistry (miscellaneous)
dc.subjectMolecular Medicine
dc.subjectPharmaceutical Science
dc.subjectDrug Discovery
dc.subjectParasitology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleBisphosphonate-based molecules as potential new antiparasitic drugsen
dc.typereview
degois.publication.firstPage2602
degois.publication.issue11
degois.publication.lastPage2621
degois.publication.titleMolecules
degois.publication.volume25
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Bisphosphonate_based_molecules_as_potential_new_antiparasitic_drugs.pdf
Tamanho:
2.91 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IHMT: PM - Artigos em revista internacional com arbitragem científica